The proposed label has been a long time in the making. More than 25 years ago, Congress directed federal agencies, including the FDA and the Centers ... are healthy or not, consumers can look ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...
Zoetis (ZTS) announced that it has updated the U.S. label for Librela, following its submission of a supplement to the FDA. This supplement ...
and Novo Nordisk can now claim to have the first medication in this class approved for chronic kidney disease. The FDA has expanded the label of Ozempic, approving the Novo Nordisk product for ...
FDA has not been alone in this interest. In 2011, in the United States, industry launched its own voluntary labeling program known as “Facts Up Front.” 5 Internationally, there has been rising ...
The company does not provide detailed information ... announced that the U.S. Food and Drug Administration (FDA) has approved an update for the label for Qelbree (viloxazine extended-release ...
The U.S. Food and Drug Administration (FDA) has published final guidance on “Communications From Firms to Health Care Providers Regarding ...
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback